Identification of traditional medicinal plant extracts with novel anti-influenza activity by Rajasekaran, Dhivya et al.
Identification of Traditional Medicinal Plant Extracts with
Novel Anti-Influenza Activity
Dhivya Rajasekaran1, Enzo A. Palombo1, Tiong Chia Yeo2, Diana Lim Siok Ley2, Chu Lee Tu2,
Francois Malherbe1, Lara Grollo1*
1 Environment and Biotechnology Centre, Faculty of Life and Social sciences, Swinburne University of Technology, Hawthorn VIC, Australia, 2 Sarawak Biodiversity Centre,
Kuching, Sarawak, Malaysia
Abstract
The emergence of drug resistant variants of the influenza virus has led to a need to identify novel and effective antiviral
agents. As an alternative to synthetic drugs, the consolidation of empirical knowledge with ethnopharmacological evidence
of medicinal plants offers a novel platform for the development of antiviral drugs. The aim of this study was to identify plant
extracts with proven activity against the influenza virus. Extracts of fifty medicinal plants, originating from the tropical
rainforests of Borneo used as herbal medicines by traditional healers to treat flu-like symptoms, were tested against the
H1N1 and H3N1 subtypes of the virus. In the initial phase, in vitro micro-inhibition assays along with cytotoxicity screening
were performed on MDCK cells. Most plant extracts were found to be minimally cytotoxic, indicating that the compounds
linked to an ethnomedical framework were relatively innocuous, and eleven crude extracts exhibited viral inhibition against
both the strains. All extracts inhibited the enzymatic activity of viral neuraminidase and four extracts were also shown to act
through the hemagglutination inhibition (HI) pathway. Moreover, the samples that acted through both HI and
neuraminidase inhibition (NI) evidenced more than 90% reduction in virus adsorption and penetration, thereby indicating
potent action in the early stages of viral replication. Concurrent studies involving Receptor Destroying Enzyme treatments
of HI extracts indicated the presence of sialic acid-like component(s) that could be responsible for hemagglutination
inhibition. The manifestation of both modes of viral inhibition in a single extract suggests that there may be a synergistic
effect implicating more than one active component. Overall, our results provide substantive support for the use of Borneo
traditional plants as promising sources of novel anti-influenza drug candidates. Furthermore, the pathways involving
inhibition of hemagglutination could be a solution to the global occurrence of viral strains resistant to neuraminidase drugs.
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Introduction
Influenza viruses are highly infective and constitute a major
causative agent for recurrent epidemics and pandemics. On
average, about 10% of the world’s population is infected by the
virus annually, resulting in around 250,000 deaths, hence posing a
serious health threat [1]. More generally, the viruses cause acute
respiratory infections referred to as ‘‘flu’’ and hospitalizations
represent a considerable financial burden upon the global
economy.
Influenza viruses are classified under the family Orthomyxovir-
idae and are divided into three types: A, B and C. The genomes of
type A and B consist of eight segments of negative-sense single-
stranded RNA and the virions express two major surface
glycoproteins, haemagglutinin (HA) and neuraminidase (NA).
Conversely, Type C contains seven RNA segments and express
only one major surface glycoprotein, hemagglutinin-esterase-
fusion (HEF) protein [2]. Amongst the types, A and B are the
predominant causes of human infections [3], with Type A being
further divided into subtypes, based on the antigenicity of the HA
and the NA. To date, 17 HA (H1–H17) and 9 NA (N1–N9)
subtypes have been identified, and most subtypes are present in
waterfowl and shorebirds [1,4,5]. Of these, only H1N1, H2N2 and
H3N2 have been associated with pandemics and epidemics in
human populations [1]. Types A and B viruses spread globally in
pandemics mediated through mutations that generate antigenic
drift and shift [6].
Vaccines form the basis for the prevention of influenza
infections, yet there are substantial drawbacks. The current
preventive strategy involves annual vaccination, requiring regular
monitoring to confirm matching between vaccines and the
circulating virus strains. Vaccination failures have been widely
documented and in the elderly, where most of the mortality
occurs, vaccines are only around 50% effective [7].
In the eventuality of a pandemic infection with a new strain,
antiviral drugs represent the first line of defence [8]. Currently
available anti-influenza drugs aim to block viral replication and
spread, thereby resulting in early recovery from the symptoms of
flu. First generation influenza antivirals, referred to as ion channel
blockers (Amantadine and Rimantadine), act on the viral M2
protein, which is essential for the organized release of nucleocapsid
after fusion of the virus with the endosomal membrane [9]. Side
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effects associated with the central nervous system and the
gastrointestinal tract, and the rapid emergence of antiviral
resistance during therapy, have limited the usefulness of
adamantanes in the prevention and treatment of influenza [10,11].
As a result, a second generation of anti-influenza drugs, the
neuraminidase inhibitors (NAI), were developed. There are
currently two NAI drugs approved for use worldwide, Oseltamivir
and Zanamivir, and two others approved in North Asia but still in
trials elsewhere (Laninamivir and Peramivir) [11]. Zanamivir
(GG167), a sialic acid analogue, and Oseltamivir, an ethyl ester
derivative of Oseltamivir GS4071, inhibit the sialidase activity of
the viral neuraminidase by competitive and irreversible binding to
the NA active site [12,13]. However, there are side effects
associated with the administration of Oseltamivir and Zanamivir,
such as nausea, vomiting, neuropsychiatric events, abdominal
pain, diarrhoea, sinusitis, headache and dizziness. Furthermore,
Oseltamivir-resistant H1N1 viruses spontaneously arose and
spread globally in 2008 [10]. These data highlight the requirement
for a third generation of anti-influenza drugs that would exhibit a
different mode of action [8]. Thirteen years after the launch of
Zanamivir and Oseltamivir, the quest for unique lead structures
remains an area of intensive research [14].
Plants represent one of the important sources of lead
compounds, with up to 40% of modern drugs being derived from
plant materials. Empirical knowledge based on the ethnomedical
benefits of plants, coupled with bioassay-guided fractionation and
isolation, has the potential to identify novel antivirals that could be
used against influenza. Currently, herb and plant resources are
relatively unlimited with respect to the search for functional
phytochemicals but these resources are dwindling rapidly due to
deforestation and advancements of industrialization. Even though
a number of studies have been performed using purified plant
chemicals, very few studies have addressed the antiviral activities
of crude plant extracts [14,15].
The search for plant-based antivirals against the influenza virus
is promising, as several plants have been shown to possess anti-
influenza activity, some of which include: Thuja orientalis, Aster
spathulifolius, Pinus thunbergia [16], Allium fistulosum [17], Sambucus
nigra [18] and Psidium guajava [19]. Active components have also
been isolated from crude plant extracts employing chemical
fractionation techniques. Patchouli alcohol isolated from the leaves
of Pogostemon cablin [20], cardiotonic glycoside obtained from
Adenium obesum (Forssk.) [21] and polyphenols from the roots of
Glycyrrhiza uralensis [14] have been shown to exhibit anti-influenza
activity. Progress in the field of anti-influenza herbal medicines has
provided alternative therapeutic measures for the treatment of
influenza virus infection. For instance, two Japanese herbal
medicines, Shahakusan and hochuekkito, have been shown to
possess in vivo activity against influenza virus [22,23]. On the other
hand, studies on Jinchai, a capsule made of Traditional Chinese
Medicine, indicated inhibitory activity against viral adsorption and
cell membrane fusion, thereby blocking transcription and replica-
tion of the virus [24]. Also, Lianhuaqingwen capsule, a natural
herbal medicine, was shown to have similar therapeutic effective-
ness to that of Oseltamivir, in terms of reducing the duration of
illness and viral shedding of Influenza A virus [25].
In this work, we have used a range of bioassays to screen fifty
medicinal plant extracts for antiviral activity against influenza
Type A viruses. The results demonstrate the anti-influenza
potential of some extracts which act via a unique mode of action
when compared to the currently available antiviral drugs. In the
eventuality of an influenza pandemic, third generation of anti-
influenza compounds would be extremely beneficial and the
source of such compounds could be medicinal plants.
Materials and Methods
Cells
Madin Darby Canine Kidney (MDCK) cells, obtained from the
American Type Culture Collection (Manassas, VA) were grown at
37uC with 5% CO2 in Roswell Park Memorial Institute medium
(RPMI; Invitrogen, No: 22400-105), supplemented with 10%
foetal bovine serum (FBS; Invitrogen, No: 16140-071) and 1%
Penicillin-Streptomycin (Invitrogen, No: 15140-122). Before add-
ing the compounds or the virus, or when quantifying the results,
the monolayers were thoroughly washed twice with phosphate
buffered-saline (PBS, pH 7.4 at room temperature). In all
experiments, the following controls were included: cell control
(cells that were not infected with the virus or treated with the plant
extracts), virus control (cells that were infected only with the virus
but not treated with the plant extracts in the antiviral assays), and
the positive controls (virus-infected cells treated with Zanamivir or
Oseltamivir).
Viruses
Type A influenza virus strains, ‘‘Mem-Bel’’ reassortant (H3N1),
a reassortant of A/Memphis/1/71 (H3N2) 6 A/Bellamy/42
(H1N1), containing the HA of A/Memphis/1/71 and the
remaining gene segments of A/Bellamy/42 and A/Puerto Rico/
8/34 (H1N1) ‘‘PR8’’ were provided by Professor Lorena Brown,
Department of Microbiology and Immunology, The University of
Melbourne, Australia. Virus stocks were grown in MDCK cells
using RPMI medium supplemented with 4 mg/mL trypsin (Sigma,
No: T1426) at 37uC in 5% CO2 for three days as described
elsewhere [26]_ENREF_16. Supernatants containing virus were
collected after cytopathic effects (CPE) were noted and antiviral
titres were determined using 50% Tissue Culture Infectious Dose,
according to Reed and Muench’s endpoint method [27], and a
colorimetric endpoint to obtain quantitative results [28]. All
aliquots of virus stocks were stored at 280uC until use.
Plant extracts
Fifty medicinal plant extracts, collected from the tropical
rainforests of Borneo, Sarawak, Malaysia, were selected on the
basis of their traditional use in healing various diseases, including
symptoms of influenza such as cough and sore throat. They were
originally extracted with a mixture of dichloromethane and
methanol in a 1:1 (v/v) ratio and subsequently concentrated using
a rotary evaporator. The yield is dependent on the part of plant
used; around 0.05 to 0.10 g of extract was obtained from 6 g of
whole plant or leaves, whereas the yield was reduced to 0.01 to
0.05 g when extracts were obtained from stems and roots. Prior to
use, the extracts were reconstituted in PBS with 10% dimethyl
sulfoxide (DMSO, SIGMA No: D 5879) and filtered using a
0.45 mm filter (Sartorius Stedium Australia No: 16533K).
Cytotoxicity studies of extracts
Briefly, MDCK cells were seeded into 96-well flat-bottomed
microtitre plates (Costar) at 46103 cells per well. Following
overnight incubation, the media of MDCK cells were aspirated,
followed by addition of 100 mL of plant extract solution diluted in
RPMI medium (two-fold dilutions, ranging from 0.78–100 mg/
mL) and another 100 mL of growth medium (supplemented
RPMI) were then added to each well. After incubation at 37uC/
5% CO2 for a further 3 days, the results were quantified using 3-
(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT, Invitrogen, No: M-6494) as per the manufacturer’s
instructions. The optical density (OD) was measured at 540 nm
using a Bio-Rad iMark TM microplate reader. The percentages of
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cell viability were based on the amount of living cells in
compound-treated cells relative to cell controls (defined as 100%
viability). Cytotoxicity graphs were then generated by plotting
percentage of cell viability versus concentration of extracts. Using
regression analysis of cytotoxicity curves (in Microsoft excel), a
trendline that best suited the curve was selected and the
corresponding equation was used to calculate 50% cytotoxic
concentrations (CC50) [29].
In vitro micro-inhibition assay
The activity of plant extracts against influenza viruses was
evaluated according to a method described elsewhere [29], albeit
some modifications. Briefly, 96-well plates were seeded with
36104 cells/well and incubated for 24 h at 37uC with 5% CO2
until a confluent monolayer was attained. The cells were washed
twice with PBS, and two-fold serial dilutions of plant extracts
(0.78–100 mg/ml) in RPMI medium were challenged with 100
TCID50 of either of the two virus strains. To all wells, 100 mL of
RPMI medium supplemented with 2 mg/mL trypsin (virus growth
medium) were added. After incubation for three days at 37uC/5%
CO2, the results were quantified as previously described. The
antiviral activity curve was then generated by plotting percentages
of virus inhibition against concentrations of extracts. IC50, the
concentration of extract essential to reduce virus-induced CPE by
50%, was expressed relative to the virus control employing dose-
response curves. Using regression analysis of antiviral activity
curves (in Microsoft excel), a trendline that best suited the curve
was selected and the corresponding equation was used to calculate
IC50 values [29].
Time-of-addition assay
The antiviral effects of extracts were evaluated at different times
of viral infection as described by Chiang et al. [30]. Briefly,
100 mL/well of each plant extract, serially diluted in RPMI at four
concentrations (0.78, 12.5, 25 and 50 mg/mL), were added to 80%
confluent MDCK cells at either 1 or 2 hours prior to infection (-1
and -2, respectively), at the time of infection (0), or 1 or 2 hours
after viral infection (+1 and +2, respectively). The infection was
performed by adding 100 mL/well of either H1N1 or H3N1 (100
TCID50). The various time points (21, 22, 0, +1, +2) were tested
independently in separate plates. 100 mL of virus growth medium
was added to each well and the plates were then incubated for
three days at 37uC/5% CO2, after which the virus inhibition was
quantified as described earlier.
Virus binding (attachment) assay
To assess the activity of the compounds in inhibiting viral
binding, an attachment assay adapted from De Logu et al. [31] was
performed. Briefly, 80% confluent cells were chilled at 4uC for
1 hour followed by infection with 50 mL/well of H1N1 or H3N1
(200 TCID50) and simultaneous supplementation with 100 mL/
well of each plant extract at four concentrations (0.78, 12.5, 25,
50 mg/ml). All plates were held at 4uC for a further 3 h, after
which the supernatant was removed; cells were washed twice with
ice-cold PBS and the medium was replaced with an equal volume
of RPMI and virus growth medium, and incubated for a further
three days at 37uC/5% CO2. MTT was employed to evaluate cell
viability and the percentage of viral inhibition was calculated in
relation to the virus control wells.
Penetration assay
The effect of plant extracts on viral penetration was studied
according to a method described elsewhere [32]. Briefly, 80%
confluent cells were chilled at 4uC for 1 hour prior to infection
with H1N1 or H3N1 (200 TCID50) in virus growth medium and
held at 4uC for further three hours. After the incubation period,
specific concentrations of extracts (0.78, 12.5, 25 or 50 mg/mL)
were added in triplicates to the wells with virus. The activity was
studied at three time intervals (30, 60 and 120 min) employing one
plate per interval at 37uC/5% CO2. After the specified time
interval, the supernatant was removed and treated with acidic PBS
(pH 3) for 1 min to inactivate unpenetrated virus [33], and finally
treated with alkaline PBS (pH 11) for neutralization. Cells were
washed once with PBS (pH 7.4) and overlaid with an equal
volume of RPMI and virus growth media. After three days
incubation at 37uC/5% CO2, cell viability was evaluated using
MTT.
Neuraminidase (NA) inhibition assay
The NA-FluorTM Influenza Neuraminidase Assay Kit (Life
Technologies, No: 4457091) was employed to test the effects of
extracts on the viral neuraminidase of both H1N1 and H3N1
strains as per the manufacturer’s instructions. The virus stock
was titrated by performing NA activity assay and the optimum
virus dilution for the neuraminidase inhibition assay was
selected. Two-fold serial dilutions of plant extracts (0.3–
25 mg/mL) were tested for NA inhibitory activity. Zanamivir
and Oseltamivir were included as positive controls in the assay
and tested at nanomolar concentrations (1022 to 104 nM).
Fluorescence was measured using a POLARstar Omega
fluorescence polarization microplate reader (excitation
355 nm, emission 460 nm). IC50 values were determined from
dose-response data using a sigmoidal curve-fitting generated and
analysed using GraphPad Prism Software.
Hemagglutination inhibition (HI) test
An HI assay was used to determine the effect of extracts on virus
adsorption [34]. Briefly, two fold serial dilutions of the extract
(0.78–100 mg/mL) were prepared in PBS and an equal volume
(25 mL/well containing 4HAU) of the virus stock was added to
each well in a round-bottomed 96-well microtitre plate in
triplicate. Subsequently, 50 mL of 5% chicken red blood cells
(CRBC) were added to all wells and mixed. The following controls
were included in every plate (i) Zanamivir (ii) Oseltamivir, (iii)
CRBC without virus, (iv) CRBC with virus devoid of extract and
(v) CRBC with extracts devoid of virus (vi) non-commercial anti-
HA MAb for H3N1 with an antibody titre of 80 and anti-HA
MAb for H1N1 with antibody titre of 200 (provided by Professor
Lorena Brown, Department of Microbiology and Immunology,
The University of Melbourne), 1:8 dilution of either of the two
antibodies in PBS were included in the assay. The hemaggluti-
nation reactions were observed after 30 minutes incubation at
room temperature.
RDE treatment
The effect of Receptor Destroying Enzyme (RDE, Denka
Seiken Co. Ltd., Tokyo, Japan) treatment upon the antiviral
activity of the extracts was studied through in vitro micro inhibition
and HI assays. The extracts were added to RDE solutions in the
ratio 1:3 and incubated at 37uC for 20 hours according to the
manufacturer’s recommendations. The purpose of this experiment
was to eliminate compounds that may possess sialic acid-like
structures which mimic the receptors of RBC and compete for
hemagglutinin [35] _ENREF_25. The extract and RDE mixture
was inactivated at 56uC for 60 minutes and then subjected to the
assays.
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Trypsin treatment
The effect of trypsin (Sigma, No: T1426) upon the antiviral
activity of the extracts was studied through an in vitro micro
inhibition assay and HI assays. The plant extracts were treated
with 4 mL of trypsin (1 mg/mL in 1% acetic acid), incubated at
37uC for 24 hours and followed by incubation at 56uC for 60
minutes before performing the assays. Plant extracts subjected to
the same temperature without trypsin and extracts that were
neither subjected to temperature nor trypsin treatments were
included as controls.
Statistical analysis
All treatments were performed in triplicates and each experi-
ment was independently repeated at least twice. The data were
expressed as mean 6 standard error of the mean (SEM). The
results of the antiviral activity assays were analysed with a one-way
ANOVA test and a significance level (p value) of 0.05 or 0.01 was
considered to compare the means.
Results
Cytotoxicity studies of plant extracts
The medicinal plant extracts were screened for cellular
toxicity in order to determine appropriate concentrations for the
in vitro micro inhibition assays. As detailed in Table 1, there
were duplicate samples among the plant extracts; extracts 13
and 30 were obtained from two sources of the same species
collected in the same location at different times while extracts 41
and 42 were obtained from different parts of the same plant. As
shown in Table 2, the concentration associated with 50%
cytotoxicity (CC50), estimated using regression analysis, was
greater than the highest tested concentration (.100 mg/mL). In
this case, the CC50 was an estimated theoretical value obtained
Table 1. Medicinal plant extracts from Sarawak demonstrating antiviral activity against H3N1 and H1N1 strains.
No
Voucher specimen
no. Plant part Botanical name (Family) Medicinal use*
8 SABC 0782 Whole plant Mussaenda elmeri (Rubiaceae) Conjunctivitis, headache
13 SABC 1753 Leaves Trigonopleura malayana (Euphorbiaceae) Cough
14 SABC 1768 Whole plant Santiria apiculata (Burseraceae) Flu, headache
29 SABC 1984 Stems Anisophyllea disticha (Anisophylleaceae) Fever
30 SABC 1996 Leaves Trigonopleura malayana (Euphorbiaceae) Cough
31 SABC 1988 Roots Trivalvaria macrophylla (Annonaceae) Flu, headache
37 SABC 3970 Stems Baccaurea angulata (Euphorbiaceae) Conjunctivitis
38 SABC 3809 Leaves Tetracera macrophylla (Dilleniaceae) Cough
41 SABC 1528 Whole plant Calophyllum lanigerum (Clusiaceae) Potential to treat AIDS
42 SABC 1528 Stems Calophyllum lanigerum (Clusiaceae) Potential to treat AIDS
43 SABC 4492 Stems Albizia corniculata (Fabaceae) Sore throat
*Information derived from; Chai 2006 [50], Salleh 2002 [51], Yaacob 2009 [52], Maji 2010 [53], Focho 2010 [54].
doi:10.1371/journal.pone.0079293.t001
Table 2. Cellular toxicity and inhibitory concentration of anti-influenza extracts against H3N1 and H1N1 strains.
Extract CC50
a (mg/mL) IC50
b (mg/mL) against H3N1 IC50
b (mg/mL) against H1N1
8 133.0614.2 19.464.5 ,0.78
13/30 130.063.5 15.562.8/6.860.2 17.060.3/13.160.5
14 136.368.2 7.362.7 9.361.5
29 157.269.6 39.366.9 37.561.5
31 106.762.1 15.661.5 6.362.0
37 149.067.1 27.261.6 17.660.6
38 165.0610.0 14.361.7 2.861.8
41/42 140.760.9 10.863.6/2.061.3 6.362.4/9.960.2
43 109.8610.1 6.760.5 1.560.7
Zanamivir 124.864.9 ,0.78 ,0.78
Oseltamivir 123.062.6 ,0.78 ,0.78
CC50
a represents the concentration of plant extract required to reduce the number of viable cells by 50% relative to control wells without test compound, calculated
from dose–response data, CC50 value estimated using regression analysis was greater than the highest tested concentration (.100 mg/mL). In this case, the result was
an estimated theoretical value obtained by extrapolation of the results in Figure 1.
IC50
b represents the concentration of plant extract needed to reduce the viral inhibition by 50% relative to virus control wells without test compound, calculated from
dose–response data of virus inhibition. Plant extracts (0.78–100 mg/mL) in RPMI medium were challenged with 100 TCID50 of either of the two virus strains.
doi:10.1371/journal.pone.0079293.t002
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by extrapolation of the results in Figure 1. Though most of the
plant extracts demonstrated minimal cytotoxicity at concentra-
tions less than 6.25 mg/mL compared to the cell control wells,
serial dilutions ranging from 0.78–100 mg/mL were chosen for
in vitro micro-inhibition assays, since the toxicity demonstrated
by the plant extracts were similar to Zanamivir and Oseltamivir
(Table 2).
Inhibitory effects of plant extracts on influenza virus
The plant extracts were subjected to a high throughput in vitro
micro-inhibition screening assay to determine antiviral activity.
Those demonstrating more than 50% viral inhibition were
deemed to have anti-influenza activity. A number of plant extracts
exhibited inhibitory activity against influenza virus strain Mem-Bel
(H3N1). However, only eleven extracts consistently reduced viral
infectivity by greater than 50% (Table 2). The same eleven
extracts also mediated significant antiviral activity against the PR8
(H1N1) strain. The antiviral activity curves for all the extracts
against H3N1 and H1N1 are shown in Figures 2 and 3,
respectively. Duplicate hits in the assay (extracts 13 and 30, and
extracts 41 and 42) confirmed the consistency of this screening
procedure. The plant extracts were most active at 12.5–50 mg/mL
with the exception of extract 29, which was active between 50–
100 mg/mL of extract.
Anti-influenza extracts studied with a time-of-addition
assay
The antiviral potentials of the eleven active extracts were tested
against H3N1 and H1N1 strains at different times (21 h, 22 h,
0 h, +1 h, and +2 h) relative to virus inoculation. All extracts
inhibited the viruses by more than 50% at all time points tested,
except for the -2 h time for extract 14 against the H1N1 strain;
12.5–50 mg/mL was most active in virus inhibition (data not
shown).
Inhibitory effects of anti-influenza extracts on the
attachment of H3N1 and H1N1
Plant extracts were tested for their ability to inhibit viral
attachment using a virus binding assay. As shown in Figure 4, nine
out of eleven extracts demonstrated more than 50% viral
inhibition against both H3N1 and H1N1 strains at 25 mg/mL.
The results support HI activity demonstrated by extracts 8, 41, 42
and 43. Despite lacking HI activity, extracts 13, 14, 30, 31 and 38
demonstrated significant inhibitory effects on the binding of
influenza virus. As expected, the established neuraminidase
inhibitors (NAI), Zanamivir and Oseltamivir, did not inhibit virus
binding. As shown in Table 3, plant extracts inhibited the binding
of H3N1 and H1N1 viruses depending on the concentration of
plant extracts used in the assay. The virus inhibition percentages of
the wells that received higher concentrations of the plant extracts
(50 or 12.5 mg/mL) were greater than the wells that were treated
with lesser concentrations of the extract (0.78 mg/mL), with the
exception of extract 14, which was inactive in inhibiting the
binding of influenza virus at 50 mg/mL but exhibited inhibitory
activity at 0.78 mg/mL against H3N1. Extract 42 was also shown
to inhibit the binding of H3N1strain at 0.78 mg/mL, at which
other extracts, except extract 14 were inactive.
Inhibitory effects of anti-influenza extracts on the
penetration of influenza virus
As shown in Table 4, all extracts were able to prevent viral
penetration, with the exception of extract 29 which was
ineffective at all time points and extract 37 which was active
only against H3N1 strain. These data support HI results
obtained using extracts 8, 41, 42 and 43. Figure 5 shows the
effects of 25 mg/mL extracts against H3N1 and H1N1 strains at
60 min. Four plant extracts (8, 30, 31 and 38) demonstrated
virus inhibition at all three time points, including the effect of
12.5 and 50 mg/mL of plant extracts at 60 min (data not
shown). For three HI extracts (41, 42 and 43), inhibition of virus
penetration increased over time as the antiviral activity of the
extract at 60 and 120 min was greater than that observed at
30 min against H3N1 strain. It is noteworthy that some extracts
lacking HI activity (13/30, 14, 31, 37 and 38) were shown to
inhibit virus penetration. Although Zanamivir and Oseltamivir
should normally act against virus release and not virus
penetration, surprisingly, 50 mg/mL Zanamivir showed 70%
viral inhibition of H3N1 after 60 min (data not shown). As
expected, Oseltamivir was inactive against both viruses in the
assay.
NA inhibitory effects of plant extracts
The influenza virus NA glycoprotein has sialidase activity and
mediates the release of viral progeny from the infected cell, thus
promoting virus transmission and spread [36]. In addition, the
viral NA removes sialic acid from glycans expressed by the viral
HA glycoprotein, thereby preventing self-aggregation of virions
[37]. All eleven extracts were tested for NA inhibitory activity
against Mem-Bel (H3N1) and PR8 (H1N1) using the NA-
FluorTM Influenza Neuraminidase Assay Kit. Increasing con-
centrations of plant extracts were associated with decreased
relative fluorescence (Table 5), consistent with inhibition of NA
activity. IC50 values indicated that extracts 8 and 43 reduced
NA activity at a lower concentration than the other extracts. It
should be noted that we have tested crude plant extracts, thus
the results cannot be directly compared with Zanamivir and
Oseltamivir, as these commercially available drugs were tested
at nanomolar concentrations.
Inhibitory effects of plant extracts on influenza virus-
induced hemagglutination
The influenza virus HA mediates attachment to the sialic acid
residues expressed by the glycoproteins and glycolipids of host
cells, which is a critical step in the initiation of infection [38].
Similarly, the viral HA binds to sialic acids expressed on the
surface of erythrocytes resulting in hemagglutination. Thus, we
examined the ability of plant extracts to inhibit virus-induced
hemagglutination using a hemagglutination inhibition (HI)
assay. As shown in Figure 6, four out of eleven extracts
mediated HI activity against Mem-Bel and PR8 viruses at
specific concentrations. Extract controls were included to study
the direct effect of extracts on chicken red blood cells in the
absence of Mem-Bel and PR8 viruses. All four HI extracts
exhibited hemolysis above 25 mg/mL in the absence of viruses.
Some hemolytic concentrations of extract control resulted in HI
Figure 1. Cytotoxicity effects of plant extracts. Following overnight incubation of cells seeded at 46103 cells per well into 96-well flat-
bottomed microtitre plates, the media were aspirated and overlaid with 100 mL of two-fold serial dilutions of plant extract (0.78–100 mg/mL) with an
additional 100 mL of growth medium (supplemented RPMI). After three days incubation, cell viability was evaluated using MTT and percentage cell
viability calculated relative to cell control wells. Representatives of two independent experiments performed in triplicate are shown. Statistical
analysis showed that data were significant with p,0.05 (one way ANOVA).
doi:10.1371/journal.pone.0079293.g001
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Figure 2. Inhibitory effects of plant extracts on H3N1 influenza virus. Cells at 80% confluency were treated with two-fold serial dilutions of
plant extract (0.78–100 mg/mL) and 100 TCID50 of H3N1 simultaneously. All wells were provided with 100 mL of RPMI medium supplemented with
2 mg/mL trypsin (virus growth medium). Cell viability was evaluated using MTT and viral inhibition percentage calculated relative to virus control
wells. Representatives of two independent experiments performed in triplicate are shown. Statistical analysis showed that data were significant with
p,0.05 (one way ANOVA).
doi:10.1371/journal.pone.0079293.g002
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Figure 3. Inhibitory effects of plant extracts on H1N1 influenza virus. Cells at 80% confluency were treated with two-fold serial dilutions of
plant extract (0.78–100 mg/mL) and 100 TCID50 of H1N1 simultaneously. All wells were provided with 100 mL of RPMI medium supplemented with
2 mg/mL trypsin (virus growth medium). Cell viability was evaluated using MTT and viral inhibition percentage calculated relative to virus control
wells. Representatives of two independent experiments performed in triplicate are shown. Statistical analysis showed that data were significant with
p,0.05 (one way ANOVA).
doi:10.1371/journal.pone.0079293.g003
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when the virus was included, suggesting that extract compo-
nents preferentially attach to the virus rather than to the
erythrocytes. Plant extracts that mediated HI activity against
Mem-Bel and PR8 strains were active in preventing virus-
induced hemagglutination at concentrations ranging between
12.5-25 mg/mL.
Effect of RDE treatment on the antiviral activity of
extracts
Four extracts which were shown to interfere with hemaggluti-
nation of chicken red blood cells were treated with RDE in order
to eliminate compounds that might contain sialic acid mimics that
compete with the RBC receptors for virus hemagglutinin. An HI
Figure 4. Inhibitory effects of plant extracts on the binding of H3N1 and H1N1 virus to MDCK cells. Cells at 80% confluency and pre-
chilled at 4uC for an hour were infected with 200 TCID50 of H1N1 or H3N1 followed by supplementation with plant extract at 25 mg/mL concentration.
After 3 h incubation at 4uC, cells were washed twice with ice-cold PBS and overlaid with RPMI and virus growth medium. Cell viability was evaluated
using MTT and viral inhibition percentage calculated relative to virus control wells. Effect of plant extracts on virus binding at a concentration of
25 mg/mL is shown. Representatives of two independent experiments performed in triplicate are shown. Statistical analysis showed that data were
significant with p,0.05 (one way ANOVA).
doi:10.1371/journal.pone.0079293.g004
Table 3. Inhibitory effects of anti-influenza extracts on the binding of H3N1 and H1N1 strains.
Extract
Percentage viral inhibition against the binding of H3N1
strain Percentage viral inhibition against the binding of H1N1 strain
Concentration (mg/mL) Concentration (mg/mL)
50 12.5 0.78 50 12.5 0.78
8 92.760.8 95.560.9 - 88.861.0 89.360.7 -
13 88.862.5 56.168.5 - 89.560.1 56.461.6 -
14 - 69.261.3 65.060.3 - 89.363.7 -
29 - - - - - -
30 88.362.4 62.861.1 - 76.063.0 - -
31 91.060.1 90.460.7 - 62.461.0 61.961.0 -
37 - - - - - -
38 69.264.5 63.263.5 - 79.063.0 82.660.43 -
41 95.460.1 87.962.0 - 89.761.3 88.160.2 -
42 90.360.3 90.160.2 57.966.5 86.860.2 88.160.6 -
43 93.560.1 93.062.8 - 83.061.5 87.260.4 -
Zanamivir - - - - - -
Oseltamivir - - - - - -
The activity of extracts against the binding of influenza virus at a concentration of 50, 12.5 and 0.78 mg/mL is shown along with standard errors. Plant extracts were
challenged with 200 TCID50 of either of the two virus strains. A negative sign indicates lack of anti-influenza activity.
doi:10.1371/journal.pone.0079293.t003
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assay was performed with RDE-treated extracts which were
originally able to prevent hemagglutination. As shown in Figure 7,
RDE treatment removed HI activity originally exhibited by all
four extracts. Further, an in vitro micro-inhibition assay was
performed with the RDE-treated extracts against H3N1 and
H1N1 viral strains. As shown in Figure 7, there was a significant
reduction in the antiviral efficacy of extracts with HI potential
whereas non-HI extract 38, included as a negative control, did not
show any significant difference in viral inhibition before and after
RDE treatment. A similar pattern in the percentage viral
inhibition was observed with the H1N1 strain exposed to RDE-
treated extracts (data not shown).
Effect of Trypsin treatment on the antiviral activity of
extracts
Plant extracts that were shown to prevent virus induced
haemagglutination were treated with trypsin in order to denature
any protein that might be the cause of such inhibition. An in vitro
micro-inhibition assay was initially performed to determine the
activity of trypsin-treated extracts and controls against H3N1 and
H1N1 strains. As shown in Figure 8, the antiviral activity of plant
extracts against the H3N1 virus was not altered by either trypsin
treatment or temperature (without trypsin). The trypsin-treated
plant extracts and controls were then subjected to an HI assay. As
shown in Figure 8, HI activity of plant extracts were exhibited
against H3N1 despite trypsin treatment or temperature change. A
similar pattern in the percentage viral inhibition and HI activity
was observed with the H1N1 strain exposed to trypsin-treated
extracts (data not shown).
Discussion
Phytomedicines have been used since ancient times to treat
various infections but clinical studies are limited [39]. In this study,
we have identified a number of traditional medicinal plant extracts
collected from Sarawak, Malaysia, which displayed anti-influenza
activity. Potentially, there are many compounds within any given
extract that might mediate antiviral activity. The antiviral
compounds present in these extracts may act alone or work in a
synergistic manner. The efficacy of several plant extracts used in
herbal medicine is directly related to the synergistic effects of
bioactive components and derivatives [40].
Safety is a major requirement for an antiviral agent and in the
search for new drugs it is important to consider possible secondary
effects. The minimal cytotoxicity observed in the extracts
investigated may be due to the presence of cytoprotective
components. This cytoprotective role of plants have been reported
in other studies on plant extracts [41]. In our study, this is an
indication that these extracts might serve as potential candidates
for the development of safe and less toxic drugs. In general,
compounds that are linked to ethnomedical uses are considered to
be safe and more effective than substances that lack this framework
[14]. Being pure drugs, Zanamivir and Oseltamivir inhibited
influenza virus at all concentrations tested (0.78 to 100 mg/mL).
Despite the difference in concentration, the anti-influenza drugs
followed concentration-independent virus inhibition. Chemical
characterization of the active components present in the plant
extracts may lead to concentration-independent virus inhibition
like that of Zanamivir and Oseltamivir. The amounts of active
component(s) present in the plant extracts and their efficiency in
preventing virus inhibition play a major role in demonstrating
antiviral activity.
All plant extracts tested were shown to exhibit NAI activity.
Extracts 8, 38 and 43 demonstrated the lowest IC50 range,
indicating a higher amount of NAI in the given plant extract or the
presence of potent NAI component(s) that may be active even at a
lower concentration. Extracts were tested at mg/mL concentra-
tions, unlike Zanamivir and Oseltamivir, which were tested at
Figure 5. Antiviral activity of plant extracts against the penetration of H3N1 and H1N1 virus at 60 min. Monolayers of MDCK cells (80%
confluent) were chilled at 4uC for an hour and then incubated with 200 TCID50 of H3N1 or H1N1 viruses at 4uC for 3 h. Plant extracts (25 mg/mL in
RPMI medium) were then added in triplicate and incubated for 60 minutes at 37uC/5% CO2. Following inactivation and neutralization of unpenetrated
virus using acidic and alkaline PBS, respectively, cells were washed with PBS and overlaid with RPMI medium and virus growth medium in equal
proportion. Cell viability was evaluated using MTT after three days of incubation at 37uC/5% CO2. Data shown are representative of two independent
experiments performed in triplicate. Statistical analysis showed that data were significant with p,0.05 (one way ANOVA).
doi:10.1371/journal.pone.0079293.g005
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nanomolar levels. Selection of mg/mL concentration range in NAI
assay relies on the likelihood that anti-influenza activity may not
be detected at very low concentrations as none of the plant extracts
showed activity at concentrations less than 3.13 mg/mL in the in
vitro micro-inhibition assays. As suggested in the literature, the
chemical components in the extracts might have combined with
the viral membrane to modify the physical properties of viral
neuraminidase [42]. Time of addition assay results also suggest the
extracts have NAI activity, since +1 h and +2 h post-infection
experiments showed more than 50% viral inhibition. Therefore,
the dose and time required for the extract to prevent viral growth
are critical and different for each.
Since drug-resistant viruses appear frequently, it is important to
identify drugs with a different mode of action to the one observed
with the conventional drugs currently used (NAI and adaman-
tanes). A sialylated molecule that can block virus attachment to
cellular receptors might act to limit the initial stages of virus
infection, compared to NA inhibition that is believed to act largely
through preventing release of new virions from virus-infected cells.
Moreover, NAI must be administered in the early stages of
infection as they are less efficient during the later phases [43]. Four
of the extracts mediated HI activity within a specific range of
concentrations. It has been reported elsewhere that in HI assays
some plant extracts can cause hemolysis at higher concentrations
[44].
Hemolysis caused by the extracts in the controls may be
attributed to the presence of other compounds apart from those
with anti-influenza activity. It is also possible that more than one
anti-influenza component may be present in extracts that showed
multiple modes of action. The stable interaction between HA and
NA, which is vital for the effective entry and release of the virus,
may have been disrupted by the anti-influenza component(s)
Table 5. Neuraminidase inhibitory activity of anti-influenza
extracts.










Antiviral drug IC50(nM) against H3N1 IC50(nM) against H1N1
Zanamivir 6.060.58 7.1260.80
Oseltamivir 6.9063.1 16.1060.30
The plant extracts’ neuraminidase inhibitory activity was measured at
concentration ranging between 0.3 to 25 mg/mL whereas the controls
Zanamivir and Oseltamivir were assayed at 0.01 to 10,000 nM as recommended
by the manufacturer. The optimum virus dilution for the neuraminidase
inhibition assay was selected by titration of virus stock in an NA activity assay;
1:8 dilution of either of the virus was selected in the NA activity assay to
perform NAI assay.
doi:10.1371/journal.pone.0079293.t005
Figure 6. Inhibitory effects of plant extracts on the hemagglutination of H3N1 and H1N1 viral strains. HI activities of four extracts (0.78–
100 mg/mL) against 4HAU/25 mL of virus are shown. The following controls were included on each plate; (i) extract controls with extract and chicken
red blood cells (CRBC) only, (ii) virus controls containing virus and CRBC and (iii) cell controls containing only CRBC. Monoclonal antibody against the
HA of either H3N1 or H1N1 strains were included as a positive control. The antibody titres for monoclonal antibody against H3N1 and H1N1 were 80
and 200, respectively; 1:8 dilution of either of the two antibodies in PBS were employed in the assay. Data are shown from one of three independent
experiments, each performed in triplicate.
doi:10.1371/journal.pone.0079293.g006
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Figure 7. Effect of RDE treatment on the antiviral activity of plant extracts. A. Inhibitory effect of plant extracts on the hemagglutination of
H3N1 viral strain. HI activities of four extracts (25 mg/mL) treated with RDE against 4HAU/25 mL of virus are shown. (i) Virus controls containing virus
and CRBC and (ii) cell controls receiving CRBC only are shown. Corresponding RDE treated monoclonal antibody which acts against the HA of
H3N1and extracts that mediate HI activity without RDE treatment were included in all plates as positive controls. The experiment was performed in
triplicate. B. Loss of efficacy in antiviral inhibition of HI extracts against H3N1 strain. An in vitro micro-inhibition assay was used to assess the ability of
plant extracts to inhibit H3N1 (100 TCID50) influenza virus. Extracts were either treated with RDE as per the manufacturer’s instructions or left in their
native form without RDE treatment. Data shown are representative of two independent experiments performed in triplicate. Statistical analysis
showed that data were significant with p,0.05 (one way ANOVA).
doi:10.1371/journal.pone.0079293.g007
Figure 8. Effect of trypsin treatment on the antiviral activity of plant extracts. A. Inhibitory effect of plant extracts on the hemagglutination
of H3N1 viral strain. HI activities of three extracts (50 mg/mL) treated with trypsin against 4HAU/25 mL of virus are shown. (i) Virus controls containing
virus and CRBC and (ii) cell controls receiving CRBC only are shown. Extracts that mediate HI activity without trypsin treatment were included in all
plates as positive controls. The experiment was performed in triplicate. B. Antiviral inhibition of HI extracts against H3N1 strain. An in vitro micro-
inhibition assay was used to assess the ability of plant extracts to inhibit H3N1 (100 TCID50) influenza virus. Extracts (3.13–100 mg/mL) were either
treated with trypsin for 24 hours at 37uC, followed by incubation at 56uC for 60 minutes or subjected to temperature without trypsin. Activity of
extracts at 50 mg/mL concentration is shown in the figure. Data shown are representative of two independent experiments performed in triplicate.
Statistical analysis showed that data were significant with p,0.05 (one way ANOVA).
doi:10.1371/journal.pone.0079293.g008
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present in the plant extracts. This could also be considered a new
anti-influenza pathway as dual action drugs have not previously
been used.
The inhibitory effects demonstrated against viral binding and
penetration further suggested the HI mode of action of extracts 8,
41, 42 and 43. Interestingly, non-HI extracts 13, 14, 30, 31, 37
and 38 which exhibited NAI activity showed significant inhibition
in the viral binding and penetration assays. The major functions of
the sialidase activity of influenza NA are to facilitate the release of
viral progeny from infected cells and enable viral spread, but NA is
also important for viral entry [44–46]. The role of NA in removing
sialic acid residues from HA could improve fusion and infectivity
of influenza virus following three mechanisms:
(i) Glycoconjugates carried by various lipids and proteins
expressed at the surface of the host cell could interfere with
the receptor binding site of HA spikes. By masking these
glycoconjugates, NA enables the binding of HA to sialic acid
receptors present at the host cell surface
(ii) Desialylation of HA by NA could also remove acid sialic
residues of HA protein, this partial unmasking could
facilitate further binding of HA to the target cell surface
receptors, thereby augmenting HA-mediated fusion
(iii) Desialylation of HA could help in the proteolytic cleavage of
the HA0 precursor into its functional subunits HA1 and
HA2, as indicated by observations where the removal of N-
glycosylation sites near HA0 cleavage site could modify its
approach to cellular proteases [46]_ENREF_36.
Thus neuraminidase also affects viral entry according to the
above-mentioned phenomena. The significant effects exhibited by
non-HI extracts in viral binding and penetration could be due to
the neuraminidase inhibitory component, which might have
played a role in inhibiting viral entry. Similar results have been
obtained in previous studies [44]. The inhibitory effect of
Zanamivir at the 60 minutes time point in the penetration assay
might have also resulted from the NAI pathway.
The loss of HI activity of the extracts following RDE treatment
suggests that the responsible components may possess sialic acid-
like structures that mimic the receptors of CRBC, thereby
competing for viral hemagglutinin. RDE-treated extracts showed
less than 50% virus inhibition in in vitro micro-inhibition assay at a
concentration of 25 mg/mL whereas native extracts which were
not treated with RDE showed significant antiviral activity at the
same concentration. Deactivation of sialic acid mimics that were
originally present in the extract may be the reason for this
significant drop in virus inhibition, though anti-influenza activity
was observed at other concentrations tested (data not shown).
Therefore, a potential synergistic effect of components apart from
those that are HAI active may be present in the plant extracts.
Further studies to investigate if there is any synergistic effect of
neuraminidase inhibitory activity and hemagglutination inhibition
exhibited by the plant extracts will be performed.
Apart from inhibiting hemagglutinin and neuraminidase, the
plant extracts could also have affected other proteins in the virus
including nucleoprotein, RNA polymerase, matrix protein1,
nuclear export protein and non-structural protein 1 that play
major roles during virus replication. Individual extract compo-
nents could attack several targets, operating in a supportive
agonistic, synergistic approach, called ‘‘synergistic multi target
effects’’ [40]. The antiviral efficacy not being affected by
temperature or trypsin treatment suggests that the compound(s)
of interest may not be proteinaceous. It is worthwhile noting that
minor variations were evident with the activity of extracts for
different batches; this could possibly result from seasonal changes
in the composition of plant extracts collected at different times or
through the collection and extraction processes. For instance,
extract 8 did not demonstrate HI activity in the most recent batch
that was used to study the effects of trypsin treatment upon the
antiviral activity of extracts, but the preliminary chemical fraction
of extract 8 demonstrated HI activity in one of the fractions. This
process is still under study. Also, the concentration at which HI
activity was shown to be present for extracts 41/42 and 43 were
different for the most recent batch unlike the results discussed in
Figure 6. HI activity was present between 50–100 mg/mL for the
most recent batch of 41/42 and 43 with HI activity being lost at
concentrations less than 50 mg/mL. This phenomenon needs to be
further examined.
The anti-influenza effects of HI extracts have not been
published previously, though some plants belonging to the same
genus have been reported to show antimicrobial activity [47–49].
Bioassay-guided fractionation of HI extracts (8, 41, 42 and 43)
coupled with HPLC and GC-MS techniques are currently being
undertaken. In vivo animal model studies that support the activity
of extracts against influenza virus should also be performed.
The results presented in this study suggest that plants with
reported medicinal properties could be a potential source for new
antiviral drugs. The plant extracts investigated could serve as
promising candidates for the development of third generation anti-
influenza drugs, thereby challenging the neuraminidase drug
resistant viruses in an attempt to safeguard human health and the
global economy.
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